AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26729277 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched hypocaloric diet (DT)
Number of subjects: 28
Study 23212185 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl patches (TFPs) 25 μg, two patches placed 12 h before surgery
Number of subjects: 40
Study 23212185 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches of identical size
Number of subjects: 40
Study 23212185 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TFPs and placebo)
Number of subjects: 40
Study 22851577 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion after exercise
Number of subjects: 8
Study 22851577 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid infusion after exercise
Number of subjects: 8
Study 22851577 — intervention group
Group type: COMPARATOR
Intervention: Intralipid infusion
Number of subjects: 8
Study 22851577 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior exercise
Number of subjects: 8
Study 21067614 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based intervention (educational symposium)
Number of subjects: 210
Study 21067614 — intervention group
Group type: COMPARATOR
Intervention: Printed copy of the clinical practice guideline (control)
Number of subjects: 210
Study 17112703 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg meloxicam
Number of subjects: 50
Study 17112703 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg meloxicam
Number of subjects: 50
Study 16314592 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention for LPSS patients
Number of subjects: 1503
Study 16314592 — intervention group
Group type: EXPERIMENTAL
Intervention: LPSS patients
Number of subjects: 1503
Study 16314592 — intervention group
Group type: COMPARATOR
Intervention: MI comparison group
Number of subjects: 1503
Study 16314592 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in ESSI score
Number of subjects: 1503
Study 11879715 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20-mg per day
Number of subjects: 50
Study 11879715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10434815 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 100
Study 10434815 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 100
Study 10434815 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 100
Study 7575120 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated limb perfusion with high flow rate (869 +/- 122 mL/min)
Number of subjects: 15
Study 7575120 — intervention group
Group type: COMPARATOR
Intervention: Isolated limb perfusion with low flow rate (286 +/- 62 mL/min)
Number of subjects: 15
Study 2322172 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resins (four types)
Number of subjects: 102
Study 6993095 — intervention group
Group type: EXPERIMENTAL
Intervention: Nova T
Number of subjects: 0
Study 6993095 — intervention group
Group type: COMPARATOR
Intervention: Copper T 200
Number of subjects: 0
Study 30826796 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous adverse event (AE) collection
Number of subjects: 184
Study 30826796 — intervention group
Group type: EXPERIMENTAL
Intervention: Details of specific prompts used to ascertain AE data
Number of subjects: 184
Study 30826796 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting of trial withdrawals
Number of subjects: 184
Study 30826796 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawals due to AEs
Number of subjects: 184
Study 30826796 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of patients with at least one event
Number of subjects: 184
Study 30826796 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal hypothesis testing for binary outcomes
Number of subjects: 184
Study 27777163 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse incision
Number of subjects: 86
Study 27777163 — intervention group
Group type: COMPARATOR
Intervention: Vertical incision
Number of subjects: 86
Study 26575524 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 μg twice per day (BID)
Number of subjects: 748
Study 26575524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 748
Study 25051209 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-Bearing (WB) exercise
Number of subjects: 65
Study 25051209 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Weight-Bearing (NWB) exercise
Number of subjects: 65
Study 25051209 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 22487032 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal learning process
Number of subjects: 0
Study 22487032 — intervention group
Group type: EXPERIMENTAL
Intervention: Striatal learning process
Number of subjects: 0
Study 22487032 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of two delta rule learning processes
Number of subjects: 0
Study 19279300 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber diet (50 g total and 25 g soluble fiber)
Number of subjects: 13
Study 19279300 — intervention group
Group type: COMPARATOR
Intervention: Moderate-fiber diet (24 g total and 8 g soluble fiber)
Number of subjects: 13
Study 17250692 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (anti-IgE) therapy
Number of subjects: 137
Study 17250692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 16241917 — intervention group
Group type: EXPERIMENTAL
Intervention: Group visits and computer-assisted consultations
Number of subjects: 116
Study 16241917 — intervention group
Group type: COMPARATOR
Intervention: Traditional out-patient consultations
Number of subjects: 116
Study 12151282 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression (measured by SelfCARE-D scale)
Number of subjects: 2584
Study 12151282 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression in males and individuals aged under 70 years
Number of subjects: 2584
Study 9523656 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 303
Study 7521090 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg DOX once in the AM
Number of subjects: 48
Study 7521090 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg DOX once in the PM
Number of subjects: 48
Study 7521090 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg DOX once in the AM
Number of subjects: 48
Study 7521090 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg DOX once in the PM
Number of subjects: 48
Study 2683019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (2 g taken 1/2 h before breakfast and at bedtime)
Number of subjects: 60
Study 2683019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29664896 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (16 mg daily for 6 weeks)
Number of subjects: 36
Study 29664896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29664896 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (in optimal treatment exposure subgroup)
Number of subjects: 36
Study 29664896 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (in individuals with high diastolic blood pressure)
Number of subjects: 36
Study 29664896 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (in individuals with low diastolic blood pressure)
Number of subjects: 36
Study 27187437 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-related self-affirming implementation intention (WS-AII)
Number of subjects: 0
Study 27187437 — intervention group
Group type: COMPARATOR
Intervention: Control implementation intention (C-II)
Number of subjects: 0
Study 26441179 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 486
Study 26441179 — intervention group
Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 486
Study 23117245 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate 1 g/day
Number of subjects: 1371
Study 23117245 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/day
Number of subjects: 1371
Study 21051493 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil concentrations (CeREMI) at 2, 4, or 6 ng m⁻¹ with propofol fixed at 3 µg ml⁻¹
Number of subjects: 0
Study 21051493 — intervention group
Group type: EXPERIMENTAL
Intervention: SPI, HR, and MAP
Number of subjects: 0
Study 18314473 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention materials of varying personalization (groups 1 and 2)
Number of subjects: 23340
Study 18314473 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 5)
Number of subjects: 23340
Study 16562414 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interview (BMI)
Number of subjects: 222
Study 16562414 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Feedback (WF)
Number of subjects: 222
Study 14601228 — intervention group
Group type: EXPERIMENTAL
Intervention: Contreet Foam dressing
Number of subjects: 25
Study 12144212 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 23
Study 12144212 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 23
Study 9627304 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist (GnRH-a) therapy
Number of subjects: 0
Study 8157550 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 400 mg i.v.
Number of subjects: 6
Study 8157550 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg po
Number of subjects: 6
Study 3277082 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (PB)
Number of subjects: 36
Study 3277082 — intervention group
Group type: COMPARATOR
Intervention: Diazepam and Phenytoin (DZ/DPH)
Number of subjects: 36
Study 31051498 — intervention group
Group type: EXPERIMENTAL
Intervention: AA-60 (8 AAs, 60 mmol/L Na+)
Number of subjects: 24
Study 31051498 — intervention group
Group type: EXPERIMENTAL
Intervention: AA-30 (5 AAs, 30 mmol/L Na+)
Number of subjects: 24
Study 31051498 — intervention group
Group type: EXPERIMENTAL
Intervention: AA-60
Number of subjects: 24
Study 31051498 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 24
Study 28691601 — intervention group
Group type: EXPERIMENTAL
Intervention: Elliptical training
Number of subjects: 27
Study 28691601 — intervention group
Group type: COMPARATOR
Intervention: Motor-assisted cycle training
Number of subjects: 27
Study 26148930 — intervention group
Group type: EXPERIMENTAL
Intervention: MPC injections (150 million cells)
Number of subjects: 60
Study 26148930 — intervention group
Group type: EXPERIMENTAL
Intervention: MPC injections (25 million cells)
Number of subjects: 60
Study 26148930 — intervention group
Group type: EXPERIMENTAL
Intervention: MPC injections (75 million cells)
Number of subjects: 60
Study 26148930 — intervention group
Group type: COMPARATOR
Intervention: Control (mock procedures)
Number of subjects: 60
Study 23930808 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaled Path Length Entropy (SPLE)
Number of subjects: 0
Study 23930808 — intervention group
Group type: COMPARATOR
Intervention: Hurst exponent
Number of subjects: 0
Study 23930808 — intervention group
Group type: COMPARATOR
Intervention: Sample entropy
Number of subjects: 0
Study 23930808 — intervention group
Group type: COMPARATOR
Intervention: Multiscale entropy
Number of subjects: 0
Study 23930808 — intervention group
Group type: EXPERIMENTAL
Intervention: Path Length Entropy (PLE)
Number of subjects: 0
Study 23930808 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate data evaluation
Number of subjects: 0
Study 21562233 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast (B)
Number of subjects: 12
Study 21562233 — intervention group
Group type: COMPARATOR
Intervention: No breakfast (NB)
Number of subjects: 12
Study 19108786 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 319
Study 19108786 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 319
Study 16816065 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine lidocaine
Number of subjects: 68
Study 16816065 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 68
Study 14641260 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthesia
Number of subjects: 140
Study 14641260 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar anaesthesia
Number of subjects: 140
Study 11187566 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecare
Number of subjects: 46
Study 11187566 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 46
Study 9132323 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac (100 mg bid)
Number of subjects: 374
Study 9132323 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg bid)
Number of subjects: 374
Study 29569943 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Body-Vibration (WBV) training on a vibration platform
Number of subjects: 50
Study 29569943 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonvibration (NVIB) training on the floor
Number of subjects: 50
Study 29569943 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 27430621 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching plus light therapy and pulsed electromagnetic field therapy for 12 weeks, twice a week for 40 min, and coaching once a fortnight for 50 min
Number of subjects: 90
Study 27430621 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with light and pulsed electromagnetic field switched to placebo settings for 12 weeks, twice a week for 40 min, and coaching once a fortnight for 50 min
Number of subjects: 90
Study 27430621 — intervention group
Group type: COMPARATOR
Intervention: Coaching alone for 12 weeks, a course of six sessions, once a fortnight for 50 min
Number of subjects: 90
Study 24726349 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3-enriched eggs (6 eggs/week)
Number of subjects: 15
Study 24726349 — intervention group
Group type: EXPERIMENTAL
Intervention: nonenriched eggs (6 eggs/week)
Number of subjects: 15
Study 24726349 — intervention group
Group type: COMPARATOR
Intervention: egg-free control
Number of subjects: 15
Study 21755540 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 2 mg BID for 2 days, then 5 mg BID for 2 days, then 10 mg BID thereafter (slow escalation)
Number of subjects: 122
Study 21755540 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg BID for 4 days, then 10 mg BID thereafter (rapid escalation)
Number of subjects: 122
Study 21755540 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg BID
Number of subjects: 122
Study 21755540 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 10 mg BID
Number of subjects: 122
Study 19634922 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase plus enoxaparin
Number of subjects: 2083
Study 19634922 — intervention group
Group type: COMPARATOR
Intervention: Fibrin-specific lytic (FSL) plus unfractionated heparin (UFH)
Number of subjects: 2083
Study 19634922 — intervention group
Group type: COMPARATOR
Intervention: Fibrin-specific lytic (FSL) plus UFH
Number of subjects: 2083
Study 19634922 — intervention group
Group type: COMPARATOR
Intervention: Fibrin-specific lytic (FSL) plus enoxaparin
Number of subjects: 2083
Study 16757862 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial neural network (ANN) classifier using [(99m)Tc]TRODAT-1 and SPECT
Number of subjects: 175
Study 16757862 — intervention group
Group type: COMPARATOR
Intervention: Conventional ROI analysis of SPECT imaging data
Number of subjects: 175
Study 14996675 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher tidal volume ventilation (12 mL/kg of predicted weight)
Number of subjects: 902
Study 14996675 — intervention group
Group type: COMPARATOR
Intervention: Lower tidal volume ventilation (6 mL/kg of predicted weight)
Number of subjects: 902
Study 14996675 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole, lisofylline, or placebo (by factorial design)
Number of subjects: 902
Study 11724641 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glutamate infusion (125 mmol x l(‐1) at a rate of 1.5 ml x h(‐1) x kg(‐1) for 1 hour)
Number of subjects: 22
Study 11724641 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (0.9% NaCl)
Number of subjects: 22
Study 9259593 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplant (LTx) subjects
Number of subjects: 22
Study 8184807 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA (n = 25)
Number of subjects: 44
Study 8184807 — intervention group
Group type: COMPARATOR
Intervention: No PTCA (n = 19)
Number of subjects: 44
Study 8184807 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ejection fraction
Number of subjects: 44
Study 3248354 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone 2.5 mg/day for 3 months
Number of subjects: 13
Study 3248354 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 13
Study 29695895 — intervention group
Group type: EXPERIMENTAL
Intervention: CBZ+BMT (Carbamazepine 200 mg, Betahistine Mesilate 12 mg or 18 mg, twice daily)
Number of subjects: 185
Study 29695895 — intervention group
Group type: COMPARATOR
Intervention: OXC+BMT (Oxcarbazepine 300 mg, Betahistine Mesilate 12 mg or 18 mg, twice daily)
Number of subjects: 185
Study 29695895 — intervention group
Group type: EXPERIMENTAL
Intervention: BMT 18 mg
Number of subjects: 185
Study 29695895 — intervention group
Group type: COMPARATOR
Intervention: BMT 12 mg
Number of subjects: 185
Study 28742880 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day ART initiation
Number of subjects: 762
Study 28742880 — intervention group
Group type: COMPARATOR
Intervention: Standard ART initiation
Number of subjects: 762
Study 26176993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitspiration images
Number of subjects: 130
Study 26176993 — intervention group
Group type: COMPARATOR
Intervention: Control set of travel images
Number of subjects: 130
Study 23406850 — intervention group
Group type: EXPERIMENTAL
Intervention: 16F foley catheter traction
Number of subjects: 88
Study 23406850 — intervention group
Group type: COMPARATOR
Intervention: 16F foley catheter without traction
Number of subjects: 88
Study 21710615 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiresorptive treatment (alendronate, clodronate, denosumab, lasofoxifene, zoledronic acid)
Number of subjects: 30118
Study 21710615 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiresorptive treatment
Number of subjects: 30118
Study 19146127 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo conditions
Number of subjects: 60
Study 19146127 — intervention group
Group type: COMPARATOR
Intervention: In vitro conditions with perfused dentin
Number of subjects: 60
Study 19146127 — intervention group
Group type: COMPARATOR
Intervention: In vitro conditions without perfused dentin
Number of subjects: 60
Study 16915526 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt test (HUT)
Number of subjects: 11
Study 16915526 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion (ISI)
Number of subjects: 11
Study 16915526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion (SLI)
Number of subjects: 11
Study 16915526 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 11
Study 14764230 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous veno-venous hemofiltration (CVVH) within 12 hours after trauma
Number of subjects: 29
Study 14764230 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with CVVH)
Number of subjects: 29
Study 14764230 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous veno-venous hemofiltration (CVVH)
Number of subjects: 29
Study 10742704 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic training on a bicycle ergometer for 30 min three times a week for 3 months, followed by a 3-month home training period.
Number of subjects: 27
Study 10742704 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in physical activities).
Number of subjects: 27
Study 9286519 — intervention group
Group type: COMPARATOR
Intervention: 1% CHX varnish (Cervitec)
Number of subjects: 82
Study 9286519 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 mixture of CHX varnish and fluoride varnish (0.1% w/w difluorsilane; Fluor Protector)
Number of subjects: 82
Study 8420236 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol
Number of subjects: 8
Study 8420236 — intervention group
Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 8
Study 3607806 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (0.5 mg/kg intravenously)
Number of subjects: 0
Study 3607806 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide 5‐mononitrate (15 mg intravenously)
Number of subjects: 0
Study 31778656 — intervention group
Group type: EXPERIMENTAL
Intervention: DSOC-guided biopsy sampling
Number of subjects: 0
Study 31778656 — intervention group
Group type: COMPARATOR
Intervention: ERCP-guided brushing
Number of subjects: 0
Study 31241519 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Fit exergame intervention
Number of subjects: 20
Study 31241519 — intervention group
Group type: COMPARATOR
Intervention: Wii video game control
Number of subjects: 20
Study 28662656 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU once a day for 2 months
Number of subjects: 72
Study 28662656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 26260043 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes group lifestyle intervention (GLI)
Number of subjects: 57
Study 26260043 — intervention group
Group type: COMPARATOR
Intervention: Dietitian referral for medical nutrition therapy (RD)
Number of subjects: 57
Study 23414196 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg/day
Number of subjects: 138
Study 23414196 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 10 mg/day
Number of subjects: 138
Study 21965488 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine (10 mg once per day before surgery, day of surgery, and first day after surgery)
Number of subjects: 50
Study 21965488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19921355 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine-propofol (KP)
Number of subjects: 280
Study 19921355 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine-remifentanil (KR)
Number of subjects: 280